Company Overview and News

0
PSU bank stocks surge up to 11% on capital infusion reports

5h thehindubusinessline
PSU bank stocks today surged up to 11 per cent amid reports that the finance ministry is likely to infuse about Rs 10,000 crore within a few days in some state-owned lenders to help them meet regulatory capital requirement.
INDIANB IOB ALBK 532418 532814 CNRYY 532179 532388 PNJZY 532121 532483 532461 CRPKY 532480 PNB CORPBANK CANBK DENABANK ANDHRABANK

0
Indian Bank - Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

0
FinMin seeks more time for PSBs to meet MPS norm

2018-07-16 freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
Indian Bank - Updates

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

0
Punjab National Bank invites bids to sell 3 NPA accounts to recover over Rs 136 crore

2018-07-06 moneycontrol
Punjab National Bank (PNB) has put on sale three non-performing assets to recover Rs 136 crore dues from the borrowers. "We intend to place these accounts for sale to ARCs/ NBFCs/other banks/FIs on the terms and conditions stipulated in the bank's policy, in line with the regulatory guidelines," PNB said in the invite for expression.
INDIANB 500116 PNJZY 532461 IDBI 532814 PNB 532401 VIJAYABANK

0
Indian Bank - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

0
Indian Bank - Investor Presentation

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

5
Bank Boards Bureau recommends 15 names for the post of MD in PSU banks

2018-06-30 livemint
Mumbai: The Bank Boards Bureau has recommended the names of 15 officials for the posts of managing director and chief executive officers in several public sector banks.
INDIANB UBNC 500116 UDBKL IDBI ALBK UBLS 532814 CNRYY 532179 SYNDIBANK 532276 532483 CRPKY UBLA 532480 CORPBANK CANBK SBAZ

0
Indian Bank - Shareholders meeting

2018-06-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

0
Indian Bank - Shareholders meeting

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIANB 532814

38
Market Live: Nifty at day#39;s high, Sensex jumps 300 pts; Europe trades strong

2018-06-29 moneycontrol
The rupee has been one of the worst performing currencies among peers. Against the USD, it has depreciated by 6.6 percent in calendar year 2018 and 8 percent, Year to Date (YTD). Adding to our concern is the increasingly hawkish Federal Reserve, which has now initiated a reversal of the Quantitative Easing (QE) – marking an end to global easy money.
BAJAJ-AUTO INDIANB 500325 IDRNF 500207 TCHQY 532712 532755 534976 5225 RCOM TORNTPOWER 522287 LHFLY 500570 500253 SUNTV RLNIY SBAZ BANG GRAPHITE 532946 JSWSTEEL TECHM TATASTEEL FORTIS TATLY LICHSGFIN Q0F 500228 RELIANCE 532814 532779 532977 532733 500470 RIGD IHHHF TATAMOTORS 509488 INDIGO HINDALCO IBN 532843 539448 HNDNF VMART ICICIBANK TTST 532174 KALPATPOWR SNQVY 500440 INDORAMA TTM

29
Market Live: Sensex extends gains, Nifty inches towards 10,700; ICICI Bank in focus

2018-06-29 moneycontrol
ICICI Bank extends gains: The country's largest private sector lender informed exchanges that the board of directors appointed Girish Chandra Chaturvedi as an additional (Independent) director effective July 1, 2018 for a period of 3 years subject to the approval of shareholders as the term of office of M K Sharma expires on June 30, 2018.
BAJAJ-AUTO INDIANB 500325 500228 IDRNF 500207 RELIANCE 532814 TCHQY 532779 532977 532755 532733 534976 500470 RIGD TORNTPOWER 522287 LHFLY 500570 TATAMOTORS 509488 500253 SUNTV RLNIY INDIGO HINDALCO BANG GRAPHITE IBN 532946 JSWSTEEL TECHM 539448 HNDNF VMART ICICIBANK TTST TATASTEEL TATLY LICHSGFIN 532174 KALPATPOWR SNQVY 500440 INDORAMA TTM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...